MedWatch

Ablynx chairman pleased with sale to Sanofi: “For the benefit of everybody”

Sanofi acquires Belgian biotech company Ablynx for almost USD 5 billion. Danish chairman Bo Jesper Hansen is very satisfied with the negotiation that was initiated after Novo Nordisk’s public offer and closed in less than three weeks.

Foto: /ritzau/Kåre Viemose

This week, Belgian antibody company Ablynx accepted an DKK 29 billion (USD 4.82 billion) offer from French Sanofi that has then outpaced Novo Nordisk in the pursuit of the company.

Danish Bo Jesper Hansen, chairman of the board in Ablynx, is pleased with the Sanofi agreement.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier